It’s a Specialty Drug World, We’re Just Living in It, Expert Says
The difference between specialty drugs and traditional drugs and how each have vied for market competition, according to Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics.
The specialty drug market now accounts for approximately 80% of drug approvals, according to Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, who recently sat down with Managed Healthcare Executive to talk about specialty drugs.
Casberg explained that while there is no textbook definition for what a specialty drug is, his company, IPD Analytics, has their own definition.
“When we get asked how we define it, we talk about high cost, high touch, basically any drug that you probably want to have a little extra guidance on, beyond retail. Now, about 80% of all approvals are considered specialty. So, there are not that many traditional drugs approved, depending on how you define it.”
The term “specialty drug” has its roots in the 1970s, when the industry formed to serve patients who needed specific treatments for conditions such as hemophilia or cancer. The recent rapid growth is fueled by technological advancements for new treatments.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Why Better Data and Awareness Matters for Medicaid Work Requirements
April 17th 2025With policymakers considering work requirements for Medicaid eligibility, Jennifer Haley, principal research associate in the Health Policy Division at the Urban Institute, said it’s more important than ever to understand how those changes could unintentionally cause harm, particularly when data systems fall short and public awareness is limited.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Medicaid Expansion Linked To Timelier Lung Cancer Surgery and Access to High-Volume Hospitals
April 17th 2025New research shows that Medicaid expansion was linked to a 2.1% increase in timely lung cancer surgeries and a 2.8% rise in procedures at high-volume hospitals, highlighting how policy changes can impact cancer care access.
Read More
